1.30Open1.50Pre Close100 Volume36 Open Interest40.00Strike Price13.10KTurnover86.20%IV6.04%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry1.32Extrinsic Value100Contract SizeAmericanOptions Type0.4207Delta0.0984Gamma33.88Leverage Ratio-0.1616Theta0.0021Rho14.25Eff Leverage0.0180Vega
Agios Pharmaceuticals Stock Discussion
$Humacyte (HUMA.US)$ : 🤔
⇨ Human Acellular Vessel (HAV)™
‣ Vascular Trauma
‣ PDUFA: 8/10/24 (BLA)
🗓️ Last Week’s AdCom & PDUFAs:
$Zevra Therapeutics (ZVRA.US)$ : Favorable AdCom 👍
🗳️ 11-5 votes in favor
⇨ Arimoclomol
‣ Niemann-Pick disease type C
‣ AdCom: 8/2/24 (NDA)
$Adaptimmune Therapeutics (ADAP.US)$ : Approved 🎉
⇨ TECELRA (afamitresgene autoleucel)
‣ Synovial sarcoma
‣ PDUFA: 8/4/24 (BLA)
$GlaxoSmithKline (GSK.US)$ : Approved 🎉
⇨ Jemperli
‣ Endometria...
HOW MANY STUPID TRADERS HERE, LOSING AND STILL TRADING 🤔🤔🤔
Bad Demon Trap = Xi Zor Gai 😏
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Liquidia (LQDA.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$MorphoSys (MOR.US)$ Phase 3
$Immunocore (IMCR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$Capricor Therapeutics (CAPR.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3 ...
In reaction to earnings/guidance:
• $AutoZone (AZO.US)$ +2.7%, $Jacobs Engineering (J.US)$ +0.9% (reaffirms Q4 EPS and adjusted EBITDA guidance)
Other news:
• $Purple Innovation (PRPL.US)$ +32.6% (confirms it received an unsolicited, non-binding proposal from Coliseum Capital Management to acquire all of the outstanding capital stock of Purple for $4.35 per share)
• $KnowBe4 (KNBE.US)$ +24.9% (received a non-binding proposal f...
In reaction to earnings/guidance:
• $Foot Locker (FL.US)$ +19.7%, $BILL Holdings (BILL.US)$ +18.1% (also names new COO), $Buckle Inc (BKE.US)$ +1.7%
Other news:
• $Axsome Therapeutics (AXSM.US)$ +33.8% (announces FDA approval of AUVELITY the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults)
• $SpringWorks Therapeutics (SWTX.US)$ +4.9% (late-breaking oral presentation of phase 3 DeFi da...
No comment yet